All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael Wang, MD Anderson Cancer Center, Houston, US. We asked, Is ibrutinib combined with venetoclax safe and effective in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
SYMPATICO: Is ibrutinib combined with venetoclax safe and effective in patients with R/R MCL?
Firstly, Wang discusses key findings from the SYMPATICO study (NCT03112174) investigating ibrutinib + venetoclax vs ibrutinib + placebo in patients with R/R MCL; results showed longer median progression-free survival with ibrutinib + venetoclax vs ibrutinib + placebo (32 months vs 22 months, respectively) and higher overall response rates (82% vs 74%, respectively). The safety profiles between both treatment arms were comparable, with fatigue, neutropenia, anemia, thrombocytopenia, and diarrhea reported as the most common adverse events of any grade. Finally, he concluded that ibrutinib + venetoclax is an effective and safe treatment option for patients with R/R MCL compared with ibrutinib + placebo, and this combination is already a standard-of-care treatment in several countries.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox